An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection

References

• Crowe SE, Solomon CG. Helicobacter pylori infection. N Engl J Med. 2019 Mar 21;380(12):1158–1165.
   PubMed Web of Science ®Google Scholar
• Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868–876.
   PubMed Web of Science ®Google Scholar
• Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014 Aug 7;20(29):9898–9911.
   PubMed Web of Science ®Google Scholar
• Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018 Nov;155(5):1372–82e17.
   PubMed Web of Science ®Google Scholar
• Cosme A, Montes M, Alonso H, et al. Quadruple with omeprazole, bismuth, tetracycline and metronidazole therapy for the eradication of Helicobacter pylori: efficacy in naive and previously treated patients with double and triple antimicrobial resistance. Jap J Gastroenterol Hepatol. 2020;4(2):1–5.
   Google Scholar
• Fiorini G, Zullo A, Saracino IM, et al. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. Scand J Gastroenterol. 2018 Jun;53(6):661–664.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016 Jul;32:84–90.
   PubMed Web of Science ®Google Scholar
• Kageyama C, Sato M, Sakae H, et al. Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan. Infect Drug Resist. 2019;12:597–602.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Nam RH, et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019 Apr;24(2):e12561.
   PubMed Web of Science ®Google Scholar
• Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018 Jul;24(7):780e5–80 e8.
   Web of Science ®Google Scholar
• Lopo I, Libanio D, Pita I, et al. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis. Helicobacter. 2018 Aug;23(4):e12493.
   PubMed Web of Science ®Google Scholar
• Mosites E, Bruden D, Morris J, et al. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist. 2018 Dec;15:148–153.
   PubMed Web of Science ®Google Scholar
• Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: past, present and future. World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):392–399.
   PubMedGoogle Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007 Aug;12(4):275–278.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212–239.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the maastricht v/florence consensus report. Gut. 2017 Jan;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019 Jul;157(1):44–53.
   PubMed Web of Science ®Google Scholar
• Ko SW, Kim YJ, Chung WC, et al. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter. 2019 Apr;24(2):e12565.
   PubMed Web of Science ®Google Scholar
• Fiorini G, Saracino IM, Zullo A, et al. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains. Helicobacter. 2017 Dec;22(6):e12448.
   PubMed Web of Science ®Google Scholar
• Zullo A, De Francesco V, Bellesia A, et al. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice. J Gastrointestin Liver Dis. 2017 Sep;26(3):225–229.
   PubMed Web of Science ®Google Scholar
• Ji Y, Lu H, Green J. Meta-analysis: high-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PloS One. 2018;13(1):e0189888.
   PubMed Web of Science ®Google Scholar
• de Boer SY, V D Meeberg PC, Siem H, et al. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. Neth J Med. 2003 Jun;61(6):218–222.
   PubMed Web of Science ®Google Scholar
• de Boer WA, Driessen WM, Potters VP, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol. 1994 Nov;89(11):1993–1997.
   PubMed Web of Science ®Google Scholar
• De Boer WA, Driessen WM, Tytgat GN. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Dec;9(6):633–638.
   PubMed Web of Science ®Google Scholar
• Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best helicobacter pylori regimen in the USA. Dig Dis Sci. 2019 Oct;64(10):2893–2898.
   PubMed Web of Science ®Google Scholar
• Yeo YH, Hsu CC, Lee CC, et al. Systematic review and network meta-analysis: comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019 Jan;34(1):59–67.
   PubMed Web of Science ®Google Scholar
• Yoon K, Kim N, Lee JW, et al. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020 Jun;25(3):e12685.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019 Apr;24(2):e12570.
   PubMed Web of Science ®Google Scholar
• Tursi A, Franceschi M, Allegretta L, et al. Effectiveness and safety of pylera(R) in patients infected by helicobacter pylori: a multicenter, retrospective, real life study. Dig Dis. 2018;36(4):264–268.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Chung JW, Woo HS, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: a prospective open-label randomized trial. World J Gastroenterol. 2019 Dec 14;25(46):6790–6798.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee SY, Kim JH, et al. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Helicobacter. 2020 Apr;25(2):e12683.
   PubMed Web of Science ®Google Scholar
• Salmanroghani H, Mirvakili M, Baghbanian M, et al. Efficacy and Tolerability of Two Quadruple Regimens: bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PloS One. 2018;13(6):e0197096.
   PubMed Web of Science ®Google Scholar
• Luo L, Ji Y, Yu L, et al. 14-day high-dose amoxicillin- and metronidazole-containing triple therapy with or without bismuth as first-line helicobacter pylori treatment. Dig Dis Sci. 2020 Feb 4. In Press.
   Web of Science ®Google Scholar
• McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020 Jan;18(1):89–98.
   PubMed Web of Science ®Google Scholar
• Lu B, Wang J, Li J, et al. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: a single-center, open-label, randomized trial. Helicobacter. 2019 Apr;24(2):e12566.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther. 2002 Mar;16(3):569–575.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Pontone S, Bellesia A, et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. Dig Liver Dis. 2018 Feb;50(2):139–141.
   PubMedGoogle Scholar
• Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905–913.
   PubMed Web of Science ®Google Scholar
• Fiorini G, Zullo A, Saracino IM, et al. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. Eur J Gastroenterol Hepatol. 2018 Jun;30(6):621–625.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Bellesia A, Ridola L, et al. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30(4):373–379.
   PubMed Web of Science ®Google Scholar
• Karamanolis GP, Daikos GL, Xouris D, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. Digestion. 2014;90(4):229–231.
   PubMed Web of Science ®Google Scholar
• Georgopoulos S, Papastergiou V, Xirouchakis E, et al. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing “concomitant” therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter. 2012 Feb;17(1):49–53.
   PubMed Web of Science ®Google Scholar
• Georgopoulos S, Papastergiou V, Xirouchakis E, et al. Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol. 2013 Mar;47(3):228–232.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013 Dec;18(6):459–467.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;51(2):145–151.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, et al. 10-day versus 14-day quadruple concomitant nonbismuth therapy for the treatment of helicobacter pylori infection: results from a randomized prospective study in a high clarithromycin resistance country. J Clin Gastroenterol. 2020 Jul;54(6):522–527.
   PubMed Web of Science ®Google Scholar
• Kapizioni C, Koutoufaris G, Ntouli V, et al. Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study. Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1206–1210.
   PubMed Web of Science ®Google Scholar
• Macias-Garcia F, Baston-Rey I, de la Iglesia-garcia D, et al. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: a prospective, cross-sectional, comparative, open trial. Helicobacter. 2019 Feb;24(1):e12546.
   PubMed Web of Science ®Google Scholar
• Alcedo J, Gracia M, Garcia-Camara P, et al. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterol Hepatol. 2020 Jun - Jul;43(6):301–309.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Lee H, Lee YC, et al. Ten-day concomitant, 10-day sequential, and 7-day triple therapy as first-line treatment for helicobacter pylori infection: a nationwide randomized trial in Korea. Gut Liver. 2019 Sep 15;13(5):531–540.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16(15):2307–2317.
   PubMed Web of Science ®Google Scholar
• Romano M, Gravina AG, Nardone G, et al. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: a real-life study. Helicobacter. 2020 Aug;25(4):e12694.
   PubMed Web of Science ®Google Scholar
• Papaefthymiou A, Liatsos C, Georgopoulos SD, et al. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: a cost-effectiveness analysis. Helicobacter. 2020 Feb;25(1):e12666.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Michopoulos S, Rokkas T, et al. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol. 2020 Mar-Apr;33(2):105–124.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 7;21(45):12954–12962.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Papastergiou V, Martinez-Gonzalez B, et al. Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial. Ann Gastroenterol. 2018 Mar-Apr;31(2):205–210.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb;12(2):177–86e3. Discussion e12-3
   PubMed Web of Science ®Google Scholar
• Lin TF, Wu DC, Tsay FW, et al. Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection. J Chin Med Assoc. 2020 Mar;83(3):233–237.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Tsay FW, Graham DY, et al. Equivalent efficacies of reverse hybrid and bismuth quadruple therapies in eradication of helicobacter pylori infection in a randomized controlled trial. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1427–1433.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Tsay FW, Kao JY, et al. Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2020 Mar 13;35:1731–1737.
   Web of Science ®Google Scholar
• De Francesco V. A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study. J Gastrointestin Liver Dis. 2019 Mar;28(1):129–130.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD. “Concomitant” or “sequential” eradication of Helicobacter pylori: which regimen comes first? Ann Gastroenterol. 2014;27(3):280–281.
   PubMedGoogle Scholar
• Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28;6:CD009034.
   PubMed Web of Science ®Google Scholar
• Sardarian H, Fakheri H, Hosseini V, et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013 Apr;18(2):129–134.
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507–514.
   PubMed Web of Science ®Google Scholar
• Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013 Jun;18(3):180–186.
   PubMed Web of Science ®Google Scholar
• Ashokkumar S, Agrawal S, Mandal J, et al. Hybrid therapy versus sequential therapy for eradication of helicobacter pylori: a randomized controlled trial. J Pharmacol Pharmacotherapeutics. 2017 Apr-Jun;8(2):62–67.
   PubMed Web of Science ®Google Scholar
• Warrington E, Lopez-Roman O, Tirado Montijo R, et al. Neither 10- nor 14-day sequential treatment is better than standard triple therapy for helicobacter pylori eradication. P R Health Sci J. 2016 Dec;35(4):203–208.
   PubMed Web of Science ®Google Scholar
• Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999 May;36(5):353–373.
   PubMed Web of Science ®Google Scholar
• Fiorini G, Saracino IM, Zullo A, et al. Antibiotic resistance and therapy for H. pylori infection in immigrant patients treated in Italy. J Clin Med. 2020 May 1;9(5):1299.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao R, Wang B, et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol. 2018 Jan;74(1):1–13.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2020 Sep 21:gutjnl-2020-321372. DOI:10.1136/gutjnl-2020-321372
   PubMed Web of Science ®Google Scholar
• Marin AC, Nyssen OP, McNicholl AG, et al. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for helicobacter pylori eradication: systematic review and meta-analysis. Drugs. 2017 May;77(7):765–776.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of helicobacter pylori infection in adults. Gastroenterology. 2016 Jul;151(1):51–69e14.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011 Dec;16(6):420–426.
   PubMed Web of Science ®Google Scholar
• Seyyedmajidi M, Abbasi L, Seyedmajidi S, et al. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori. Caspian J Intern Med. 2019;10(2):211–216. Spring
   PubMed Web of Science ®Google Scholar
• Tariq H, Patel H, Kamal MU, et al. Reevaluation of the efficacy of first line regimen for helicobacter pylori. Clin Exp Gastroenterol. 2020;13:25–33.
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent helicobacter pylori infection: a meta-analysis. CME. Am J Gastroenterol. 2006 Mar;101(3):488–496.
   PubMed Web of Science ®Google Scholar
• Liou JM, Bair MJ, Chen CC, et al. Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: a randomized trial. Am J Gastroenterol. 2016 Mar;111(3):381–387.
   PubMed Web of Science ®Google Scholar
• Liou JM, Chen PY, Chen CC, et al. Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori-a multicenter randomized trial. Gut. 2019;68(Suppl1):A84.
   Google Scholar
• Chang YL, Tung YC, Tu YK, et al. Efficacy of second-line regimens for Helicobacter pylor eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 Sep;7(1):e000472.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015 Apr;41(8):768–775.
   PubMed Web of Science ®Google Scholar
• Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10):1185–1190.
   PubMed Web of Science ®Google Scholar
• Wu TS, Hsu PI, Kuo CH, et al. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis. 2017 Sep;18(9):537–542.
   PubMed Web of Science ®Google Scholar
• Gan HY, Peng TL, Huang YM, et al. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: a Prospective, Single-Center, randomized clinical trial. Sci Rep. 2018 Jun 13;8(1):9045.
   PubMedGoogle Scholar
• Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol. 2019 Jul 25;19(1):132.
   PubMedGoogle Scholar
• Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995 May;108(5):1412–1417.
   PubMed Web of Science ®Google Scholar
• Kayser S, Flury R, Zbinden R, et al. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer]. Schweizerische Medizinische Wochenschrift. 1997 Apr 26;127(17):722–727.
   PubMedGoogle Scholar
• Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015 Oct-Dec;28(4):448–451.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Shiotani A, Graham DY. Current and future treatment of helicobacter pylori infections. Adv Exp Med Biol. 2019;1149:211–225.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu YJ, Zhao Z, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol. 2020 May;32(5):563–568.
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019 Jun 1;74(6):1718–1724.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of helicobacter pylori. Am J Gastroenterol. 2019 Mar;114(3):437–445.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang JX, Han SX, et al. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Feb;98(7):e14396.
   PubMed Web of Science ®Google Scholar
• Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019 Aug;24(4):e12596.
   PubMed Web of Science ®Google Scholar
• Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug;25(4):e12692.
   PubMed Web of Science ®Google Scholar
• Zullo A. The current role of dual therapy for treatment of Helicobacter pylori: back to the future? Eur J Gastroenterol Hepatol. 2020 May;32(5):555–556.
   PubMed Web of Science ®Google Scholar
• El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447–460.
   PubMed Web of Science ®Google Scholar
• Lam SK. Differences in peptic ulcer between East and West. Bailliere’s Best Pract Res Clin Gastroenterol. 2000 Feb; 14(1):41–52.
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Aftab H, Shrestha PK, et al. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control. 2019;8:40.
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Cruz M, Doohan D, et al. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PloS One. 2019;14(3):e0213868.
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Fagoonee S, Astegiano M, et al. Rifabutin-based rescue therapy for helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients. J Clin Med. 2019 Feb 6;8(2):199.
   Web of Science ®Google Scholar
• Saracino IM, Pavoni M, Zullo A, et al. Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for helicobacter pylori infection. Eur J Intern Med. 2020 Jul 6. DOI:10.1016/j.ejim.2020.06.029.
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Lin CY, Le PH, et al. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol. 2020 Jul 10;20(1):218.
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013 Feb;14(2):211–223.
   PubMed Web of Science ®Google Scholar
• Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020Jun16;172(12):795–802.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Ierardi E, Hassan C, et al. Furazolidone therapy for Helicobacter pylori: is it effective and safe? World J Gastroenterol. 2009 Apr 21;15(15):1914–1915.
   PubMedGoogle Scholar
• Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2012 Jan-Feb; 18(1):1–2.
   PubMed Web of Science ®Google Scholar
• Zhuge L, Wang Y, Wu S, et al. Furazolidone treatment for Helicobacter Pylori infection: a systematic review and meta-analysis. Helicobacter. 2018 Apr;23(2):e12468.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018 Oct 28;24(40):4596–4605.
   PubMed Web of Science ®Google Scholar
• Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter. 2019 Aug;24(4):e12591.
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Samadi A, Joukar F, et al. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. Excli J. 2019;18:644–652.
   PubMed Web of Science ®Google Scholar
• Mori H, Suzuki H, Matsuzaki J, et al. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy. Digestion. 2020;101(5):644-650..
   PubMedGoogle Scholar
• Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy. Gastroenterol Res Pract. 2012;2012:757926.
   PubMed Web of Science ®Google Scholar
• Papastergiou V, Georgopoulos SD, Karatapanis S. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. Curr Pharm Des. 2014;20(28):4521–4532.
   PubMed Web of Science ®Google Scholar
• Yu L, Luo L, Long X, et al. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol. 2019;12:1756284819874922.
   Web of Science ®Google Scholar
• Argueta EA, Moss SF. Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 Aug;50(3):331–332.
   PubMed Web of Science ®Google Scholar
• Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 Jun;49(11):1385–1394.
   PubMed Web of Science ®Google Scholar
• Lopez-Gongora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother. 2015 Sep;70(9):2447–2455.
   PubMed Web of Science ®Google Scholar
• Pan J, Shi Z, Lin D, et al. Is tailored therapy based on antibiotic susceptibility effective? A multicenter, open-label, randomized trial. Front Med. 2020 Feb;14(1):43–50.
   PubMed Web of Science ®Google Scholar
• Cambau E, Allerheiligen V, Coulon C, et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 2009 Nov;47(11):3600–3607.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006 Jan 17;144(2):94–100.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Zullo A, Giorgio F, et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol. 2014 Mar;63(Pt 3):453–457.
   PubMedGoogle Scholar
• Graham DY, Kudo M, Reddy R, et al. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter. 2005 Feb;10(1):1–3.
   PubMed Web of Science ®Google Scholar
• Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S171–4.
   PubMed Web of Science ®Google Scholar
• Liou JM, Chen PY, Luo JC, et al. Efficacies of genotypic resistance-guided vs empirical therapy for refractory helicobacter pylori infection. Gastroenterology. 2018 Oct;155(4):1109–1119.
   PubMed Web of Science ®Google Scholar
• Kwon YH, Jeon SW, Nam SY, et al. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: a single-center prospective pilot study. Helicobacter. 2019 Aug;24(4):e12585.
   PubMed Web of Science ®Google Scholar
• Papastergiou V, Mathou N, Licousi S, et al. Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective. Ann Gastroenterol. 2018 Mar-Apr;31(2):198–204.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Yamaoka Y. Role of vonoprazan in helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2018;9:1560.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018 Feb;154(3):462–466.
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016 May;43(10):1048–1059.
   PubMed Web of Science ®Google Scholar
• Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019;2019:9781212.
   PubMed Web of Science ®Google Scholar
• Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018 Aug;23(4):e12495.
   PubMed Web of Science ®Google Scholar
• Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of helicobacter pylori. Digestion. 2019 Aug 21:1–9. DOI:10.1159/000502287
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020 Jun;69(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2020 Jan 8:1–7. doi10.1159/000504939.
   PubMedGoogle Scholar
• Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019 Apr;34(4):686–692.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Yamada A, Niikura R, et al. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single-arm study. Helicobacter. 2020 Oct;25(5):e12719..
   PubMed Web of Science ®Google Scholar
• Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen? Appl Microbiol Biotechnol. 2019 Feb;103(4):1573–1588.
   PubMed Web of Science ®Google Scholar
• Zhou BG, Chen LX, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019 Oct;24(5):e12651.
   PubMed Web of Science ®Google Scholar
• Asgari B, Kermanian F, Hedayat Yaghoobi M, et al. The Anti-Helicobacter pylori Effects of Lactobacillus acidophilus, L. plantarum, and L. rhamnosus in Stomach Tissue of C57BL/6 Mice. Visc Med. 2020 Apr;36(2):137–143.
   PubMed Web of Science ®Google Scholar
• Chen YH, Tsai WH, Wu HY, et al. Probiotic Lactobacillus spp. act against helicobacter pylori-induced inflammation. J Clin Med. 2019 Jan 14;8(1):90.
   Web of Science ®Google Scholar
• Liu A, Wang Y, Song Y, et al. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2020 Mar-Apr;26(2):78–83.
   PubMed Web of Science ®Google Scholar
• Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore). 2019 Apr;98(15):e15180.
   PubMed Web of Science ®Google Scholar
• Dore MP, Bibbo S, Pes GM, et al. Role of probiotics in helicobacter pylori eradication: lessons from a study of lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475 (Gastrus(R)) and a proton-pump inhibitor. Can J Infect Dis Med microbiol. 2019;2019:3409820. = Journal canadien des maladies infectieuses et de la microbiologie Med.
   PubMed Web of Science ®Google Scholar
• Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: a review. Biomed Pharmacothe. 2019 Mar;111:537–547.
   PubMed Web of Science ®Google Scholar
• Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep. 2012 Mar 27:2012:bcr0620114412.
   Google Scholar
• Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000 Oct;14(10):1267–1272.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep;44(3):537–563.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America (IDSA). White paper: reccomendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012 Oct;55(8):1031–1046.
   PubMed Web of Science ®Google Scholar